535 related articles for article (PubMed ID: 24613684)
1. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
2. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
Mitin T; Hunt D; Shipley WU; Kaufman DS; Uzzo R; Wu CL; Buyyounouski MK; Sandler H; Zietman AL
Lancet Oncol; 2013 Aug; 14(9):863-72. PubMed ID: 23823157
[TBL] [Abstract][Full Text] [Related]
3. Trimodality therapy in bladder cancer: who, what, and when?
Premo C; Apolo AB; Agarwal PK; Citrin DE
Urol Clin North Am; 2015 May; 42(2):169-80, vii. PubMed ID: 25882559
[TBL] [Abstract][Full Text] [Related]
4. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
Alfred Witjes J; Max Bruins H; Carrión A; Cathomas R; Compérat E; Efstathiou JA; Fietkau R; Gakis G; Lorch A; Martini A; Mertens LS; Meijer RP; Milowsky MI; Neuzillet Y; Panebianco V; Redlef J; Rink M; Rouanne M; Thalmann GN; Sæbjørnsen S; Veskimäe E; van der Heijden AG
Eur Urol; 2024 Jan; 85(1):17-31. PubMed ID: 37858453
[TBL] [Abstract][Full Text] [Related]
5. Is trimodal therapy the current standard for muscle-invasive bladder cancer?
López Valcárcel M; Barrado Los Arcos M; Ferri Molina M; Cienfuegos Belmonte I; Duque Santana V; Gajate Borau P; Fernández Ibiza J; Álvarez Maestro M; Sargos P; López Campos F; Couñago F
Actas Urol Esp (Engl Ed); 2024 Apr; ():. PubMed ID: 38575067
[TBL] [Abstract][Full Text] [Related]
6. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
Efstathiou JA; Bae K; Shipley WU; Kaufman DS; Hagan MP; Heney NM; Sandler HM
J Clin Oncol; 2009 Sep; 27(25):4055-61. PubMed ID: 19636019
[TBL] [Abstract][Full Text] [Related]
7. Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?
Gofrit ON; Meirovitz A; Frank S; Rabinovich I; Luwisch H; Yutkin V; Neuman T; Hidas G; Duvdevani M; Wygoda M
Cancer Med; 2020 Nov; 9(22):8491-8497. PubMed ID: 32960495
[TBL] [Abstract][Full Text] [Related]
8. A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.
Cao C; Fu Z; Liu Y; Zhou A; Wang J; Shou J
Front Immunol; 2021; 12():684879. PubMed ID: 34177933
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis.
Bamias A; Tsantoulis P; Zilli T; Papatsoris A; Caparrotti F; Kyratsas C; Tzannis K; Stravodimos K; Chrisofos M; Wirth GJ; Skolarikos A; Mitropoulos D; Constantinides CA; Deliveliotis C; Iselin CE; Miralbell R; Dietrich PY; Dimopoulos MA
Cancer Med; 2016 Jun; 5(6):1098-107. PubMed ID: 27004619
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
[TBL] [Abstract][Full Text] [Related]
11. Organ preservation in muscle-invasive urothelial bladder cancer.
Niglio SA; Purswani JM; Schiff PB; Lischalk JW; Huang WC; Murray KS; Apolo AB
Curr Opin Oncol; 2024 May; 36(3):155-163. PubMed ID: 38573204
[TBL] [Abstract][Full Text] [Related]
12. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
[TBL] [Abstract][Full Text] [Related]
13. Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Ham WS; Park JS; Jang WS; Kim J
Ann Surg Oncol; 2024 Feb; 31(2):1384-1392. PubMed ID: 37884699
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
Rose TL; Deal AM; Ladoire S; Créhange G; Galsky MD; Rosenberg JE; Bellmunt J; Wimalasingham A; Wong YN; Harshman LC; Chowdhury S; Niegisch G; Liontos M; Yu EY; Pal SK; Chen RC; Wang AZ; Nielsen ME; Smith AB; Milowsky MI;
Bladder Cancer; 2016 Oct; 2(4):405-413. PubMed ID: 28035321
[No Abstract] [Full Text] [Related]
15. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
Ditonno F; Veccia A; Montanaro F; Pettenuzzo G; Franco A; Manfredi C; Triggiani L; De Nunzio C; De Sio M; Cerruto M; Crivellaro S; Kutikov A; Autorino R; Antonelli A
BJU Int; 2024 Apr; ():. PubMed ID: 38622957
[TBL] [Abstract][Full Text] [Related]
16. Surgery versus radiotherapy for muscle invasive bladder cancer.
Shelley MD; Barber J; Mason MD
Cochrane Database Syst Rev; 2001; 2001(3):CD002079. PubMed ID: 11687012
[TBL] [Abstract][Full Text] [Related]
17. Bladder-Preserving Trimodality Therapy With Capecitabine.
Lynch C; Sweis RF; Modi P; Agarwal PK; Szmulewitz RZ; Stadler WM; O'Donnell PH; Liauw SL; Pitroda SP
Clin Genitourin Cancer; 2024 Apr; 22(2):476-482.e1. PubMed ID: 38228414
[TBL] [Abstract][Full Text] [Related]
18. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
Swinton M; Mariam NBG; Tan JL; Murphy K; Elumalai T; Soni M; Ferrera A; Richardson C; Walshaw R; Mistry H; Ramani V; Song Y; Birtle A; Henry A; Chan J; Hoskin P; Choudhury A
J Clin Oncol; 2023 Sep; 41(27):4406-4415. PubMed ID: 37478391
[TBL] [Abstract][Full Text] [Related]
19. Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer.
Swinton M; Devi A; Song YP; Hoskin P; Choudhury A
World J Urol; 2024 Apr; 42(1):210. PubMed ID: 38573431
[TBL] [Abstract][Full Text] [Related]
20. A balanced perspective on bladder preservation and systemic treatment in muscle-invasive bladder cancer.
Lin FX; Wang L; Xu ZP
World J Urol; 2024 May; 42(1):288. PubMed ID: 38700672
[No Abstract] [Full Text] [Related]
[Next] [New Search]
